FDA Warns Companies Hawking ‘Legal Morphine' Products
'This action reflects the agency's growing concern around novel potent opioid products being marketed to US consumers and sold online and in smoke shops, gas stations, and corner stores,' the FDA said in a statement.
Since late 2023, there has been a surge in 'kratom' products marketed as '7-OH,' '7-Hydro,' or 'legal morphine,' as reported by Medscape Medical News.
7-OH occurs naturally in trace amounts in kratom. By contrast, concentrated 7-OH preparations are 30-40 times more potent at opioid receptors and produce rapid-onset analgesia, euphoria, respiratory depression, and classic opioid-type withdrawal.
As previously reported by Medscape Medical News, research has shown that 7-OH has high abuse potential and may also increase the intake of other opiates.
The FDA warning letters focus on companies illegally selling tablets, gummies, drink mixes, shots, and other products that contain 7-OH as an added ingredient or at concentrated levels.
According to the agency, some products are adulterated conventional foods or dietary supplements because 7-OH does not meet the relevant safety standard. Others are unapproved new drugs with unproven claims such as relieving pain and managing anxiety, the FDA said.
'7-OH is not lawful in dietary supplements and cannot be lawfully added to conventional foods. Additionally, there are no FDA-approved drugs containing 7-OH, and it is illegal to market any drugs containing 7-OH,' the FDA warned.
The warning letters were sent to the following companies:
Images of the products being illegally marketed by the seven companies that received warning letters can be viewed online.
The FDA has requested a response from each company within 15 business days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Ekso Bionics Holdings Inc (EKSO) Q2 2025 Earnings Call Highlights: Navigating Revenue Decline ...
Revenue: $2.1 million for Q2 2025, down from $5 million in Q2 2024. Gross Profit: $800,000 for Q2 2025, compared to $2.6 million in Q2 2024. Gross Margin: Approximately 40% for Q2 2025, down from 53% in Q2 2024. Operating Expenses: $4.8 million for Q2 2025, a 4% decrease from $5 million in Q2 2024. Net Loss: $2.7 million for Q2 2025, or $1.24 per share, compared to $2.4 million, or $1.99 per share, in Q2 2024. Cash and Restricted Cash: $5.2 million as of June 30, 2025. Personal Health Product Revenue Growth: More than 50% increase in the first half of 2025 compared to the same period in 2024. Warning! GuruFocus has detected 2 Warning Signs with EKSO. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ekso Bionics Holdings Inc (NASDAQ:EKSO) is confident in closing a significant portion of deferred multi-device Enterprise Health sales by year-end. The company has launched eksoUniversity, a virtual platform providing continuing education courses to physical therapists, which could generate incremental revenue. Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025. Ekso Bionics Holdings Inc (NASDAQ:EKSO) has partnered with PRIA Healthcare to enhance market access and commercialization of the Ekso Indego Personal device. The company is leveraging AI capabilities through the NVIDIA Connect program to enhance its exoskeleton technology platforms. Negative Points Ekso Bionics Holdings Inc (NASDAQ:EKSO) experienced a significant revenue decline in Q2 2025, with revenues dropping to $2.1 million from $5 million in Q2 2024. Gross profit and gross margin decreased due to lower Enterprise Health device sales and increased shipping costs. The company reported a net loss of $2.7 million for Q2 2025, compared to a net loss of $2.4 million in Q2 2024. There are short-term delays in completing significant multi-device Enterprise Health sales, impacting revenue. A small percentage of US customers have delayed purchases due to loss of federal grants and economic uncertainties. Q & A Highlights Q: Can you quantify the deferred sales on the Enterprise Health side and how much you expect in the back half of the year? A: Scott Davis, CEO, explained that two multiunit device sales were delayed, one international order due to regulatory challenges expected to occur in 2025, and a North American IDN order expected in Q3, totaling about $1.4 million. Q: When do you expect the Indego Personal to overtake the Enterprise Health business? A: Scott Davis, CEO, indicated that while Indego Personal represented about 10% of revenue in 2024, it is expected to contribute closer to 25% in 2025. By 2027, it is anticipated to overtake the Enterprise Health business. Q: How is the process of nailing down the patient profile and claims for Indego Personal progressing? A: Scott Davis, CEO, noted progress in the appeals process, with positive outcomes reaffirming medical necessity. They are working with DME and O&P partners to ensure strong claims submissions, aiming for routine approvals. Q: Will eksoUniversity focus solely on exoskeletons, or will it include other content? A: Scott Davis, CEO, stated that while initial courses focus on exoskeleton technology, eksoUniversity will cover a wide range of neuro rehabilitation topics, leveraging contributions from neuro PTs within their ecosystem. Q: What steps are being taken to ensure growth in enterprise sales, and how long will it take? A: Scott Davis, CEO, mentioned that they are working to close deferred deals and exploring options like third-party financial partners to help customers with budget constraints. They are optimistic about pulling in deferred deals in Q3. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Medscape
an hour ago
- Medscape
Refine Your Application as Residency Deadline Approaches
The deadline for applying to residency programs is approaching, and as you prepare to apply to your chosen programs, here are some strategies to streamline the process while you get your plans and materials in order. Ensure Your Residency Portfolio Is Ready Consider these tips to keep you on track and organized. Start early and get organized. Whether your specialty uses Electronic Residency Application Service (ERAS) or another application platform, timelines with all key dates for the season are out. Keep this information handy and set alerts so you stay on track, recommended Meredith C. Thompson, MD, MAEd, associate professor and interim vice chair of Education, and interim assistant dean of student affairs, Department of Emergency Medicine, College of Medicine, University of Florida Health/Shands Hospital in Gainesville, Florida. The ERAS system begins accepting applications on September 3. Do your research. 'Formulate a system to compare and keep track of all the programs you're interested in. This includes any program characteristics that are important to you and your perceived competitiveness for the program. Your advisor can help with that, as can reputable data sources like Texas Star, AAMC [Association of American Medical Colleges] residency explorer or other specialty organization advising resources,' Thompson said. Another tip: Many programs also maintain social media presence and host virtual meet and greets on these platforms for applicants. Concentrate on recommendations. Ask for letters of recommendation at least 1 month in advance. 'Your goal is to have all application elements submitted by the time the platform opens to programs for viewing,' advised Thompson. Ensuring all items are received on time is key to maximizing your chances of obtaining interviews, she said. Meredith C. Thompson, MD, MAEd Assemble your team. Applying to residency is not a solo endeavor, so Thompson explained it's in your best interest to build a team to support you during the process. 'Key persons to have in your corner include a specialty specific advisor, editor, and interview preparer,' she said. Check your medical school's resources as many institutions provide students with access to a specialty specific advisor that can provide evidenced based advice personalized to your unique situation during the application process. If this is not available, Thompson recommended connecting to your student affairs dean who typically can help you with this information or guide you to appropriate data sources to help make these decisions. Lean on a support team. Complete one or more practice interviews with someone familiar with the interview format for your chosen specialty to become more comfortable, she suggested. 'Your support team is key in ensuring you are putting your best foot forward during the application and interview process,' Thompson said. Proofread your materials. Make sure all sections are completed and that your information is free from typos, said Mitchell Goldman, MD, senior associate dean for graduate medical education, professor of medicine, and designated institutional official at the University of Missouri School of Medicine in Columbia, Missouri. 'You want to impress anyone who reads your application and leave an impression of professionalism,' Goldman stated. 'Recommend having an experienced educator review your personal statement before submission to identify opportunities for improvement.' Be honest and genuine in your application. Goldman said to list hobbies, interests, and volunteer experiences that you could discuss in detail if asked about them during an interview. Be realistic in the scope. If you are applying to highly competitive specialties, consider a back-up plan and apply to acceptable programs or specialties, Goldman said. 'You want to be realistic about the programs you apply to and have a good chance for getting an interview at a number of programs,' he said. Be proactive. Reach out early and often for guidance from trusted sources. They may have prudent advice to share. In addition, be sure to follow-up. If your dream program hasn't extended an interview, consider sending an email to the program director and coordinator. 'Send only one (follow-up) email to communicate genuine interest,' Thompson said. 'Application season is not the time to take a wait and see approach.' How do you use your medical school's resources to help with the process? Your medical school's student affairs office is a wealth of information for your residency-application process. They can provide guidance on evidence-based resources to inform your decision making. Also, your medical school may have a career advising program that can identify local specialty specific advisors to give personalized guidance. 'In addition to this, they can be a resource to review personal statements, provide mock practice interviews, and assess your total application for your competitiveness for different programs,' Thompson said. Finally, medical school alumni programs can also be a resource for these types of services. What do these experts say about the rewards of residency? Residency allows you to focus on your unique interests and talents. 'This is rewarding as it allows you to enhance your clinical skills to more meaningfully contribute to patient care in a particular niche as well as develop professionally under the guidance of experts and a network of physicians with similar career goals,' said Thompson. 'Moreover, you gain a cadre of coresidents that share the journey with you that you can learn from and lean on for support.' Your residency is also a time where you can be immersed in your area of interest, be educated by those with extensive expertise and teaching skills and a time of rapid growth in your personal and professional life, said Goldman. 'Residency experiences are some of the most rewarding experiences of a physician's life,' he said. 'It is also a time to have fun being with individuals with shared interest. You can make life-long friends, learn about yourself and what you value most moving forward.'
Yahoo
an hour ago
- Yahoo
Shelby Lambdin appointed to four-month stint on Spokane City Council
Jul. 28—Shelby Lambdin was appointed to a four-month stint on the Spokane City Council Monday, filling a seat representing south Spokane vacated by former Councilwoman Lili Navarrete, who was herself appointed to the seat in early 2024 and resigned effective July 1 citing health concerns. Lambdin is the population health director at the Community Health Association of Spokane, more commonly known as CHAS Health. She was appointed with a 4-2 vote; Councilmen Jonathan Bingle and Michael Cathcart opposed her appointment. Though voters will have an opportunity in November to choose a successor for a full four-year term — Kate Telis and Alejandro Barrientos are currently vying for the seat — the City Council is responsible for appointing a temporary replacement when a seat is vacated early. Bingle and Cathcart had advocated to appoint Ryan Oelrich, who served on the City Council during a roughly two-month stint in 2023, arguing that the experience would make it easier for Oelrich to hit the ground running as the council prepares to balance the city's budget in the coming months. Ahead of the vote, Councilman Paul Dillon thanked the applicants for the position but said he and Council President Betsy Wilkerson had wanted to bring on a new voice to the council. Lambdin has no political, elected or government experience. During her public interview, Lambdin argued her experience in public health would bring expertise to the council on addressing relevant issues. She advocated for reducing the city's costs by using technology and artificial intelligence to replace personnel and streamline operations. Lambdin also argued in favor of programs to make the city's outdoor recreation more accessible to marginalized communities and for advancing the council's work on making various services available in other languages. Solve the daily Crossword
